Bisphosphonates in osteoporosis

Review overemphasises benefits and downplays serious harms

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e5989 (Published 10 September 2012)
Cite this as: BMJ 2012;345:e5989

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Vijaya Musini, assistant professor1,
  2. Barbara Mintzes, assistant professor1,
  3. Aaron Tejani, researcher, therapeutics initiative1,
  4. James M Wright, professor1
  1. 1Departments of Anesthesiology, Pharmacology and Therapeutics, and Medicine, University of British Columbia, BC, Vancouver, Canada V6T 1Z3
  1. vijaya{at}ti.ubc.ca

We recently conducted a systematic review of bisphosphonates in postmenopausal women with osteoporosis. Our critical appraisal of evidence from 33 randomised controlled trials (25 375 women) of at least one year’s duration reached different conclusions from those of Poole and Compston.1 2

The goal of treatment is prevention of fragility fractures. Effects on bone mineral …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL